ERBB2 and breast cancer: This prospective cohort study provides real‐world data on the use of the Oncotype DX test in women over 70 years old with HR‐positive, HER2‐negative early breast cancer (eBC), describing patient/tumor characteristics, oncogeriatric evaluations, and survival analyses (IDFS, OS) in the tested population.